Simplex Trading
MLYS icon

Simplex Trading’s Mineralys Therapeutics MLYS Stock Holding History

Simplex Trading’s Portfolio MLYS Stock Details MLYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$1.26M Buy
50,100
+5,600
+13% +$152K ﹤0.01% 2468
2026
Q2 		$1.2M Buy
44,500
+34,200
+332% +$938K ﹤0.01% 2586
2026
Q1 		$279K Buy
10,300
+9,800
+1,960% +$287K ﹤0.01% 3902
2025
Q4 		$18.1K Sell
500
-2,600
-84% -$104K ﹤0.01% 6569
2025
Q3 		$117K Buy
3,100
+2,200
+244% +$47.6K ﹤0.01% 5560
2025
Q2 		$12K Sell
900
-5,000
-85% -$72.5K ﹤0.01% 7178
2025
Q1 		$93K Buy
5,900
+5,800
+5,800% +$66.7K ﹤0.01% 5123
2024
Q4 		$1K Sell
100
-600
-86% -$7.85K ﹤0.01% 8259
2024
Q3 		$8K Sell
700
-900
-56% -$10.9K ﹤0.01% 7343
2024
Q2 		$18K Buy
+1,600
New +$20.2K ﹤0.01% 6984

Other funds holding MLYS

Catalys Pacific
Catalys Pacific Tokyo, Japan $210M AUM 33.18% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
Laurion Capital Management
Laurion Capital Management New York $6.21B AUM 32.28% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Andera Partners
Andera Partners Paris $176M AUM 1.8% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $106B AUM 32.76% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $72.4B AUM 31.32% 1-Year Est. Return
Candriam SCA
Candriam SCA Strassen, Luxembourg, Luxembourg $22.5B AUM 50.38% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $420B AUM 34.97% 1-Year Est. Return

Simplex Trading's MLYS Position: Q3 2026 in Review

Simplex Trading reduced its Mineralys Therapeutics (MLYS) stake by 9.7% in Q3 2026, selling an estimated $94.5K and leaving 32,507 shares worth $817K. The position accounts for ﹤0.01% of the portfolio, ranked #2976.

Simplex Trading first reported a position in MLYS in Q3 2024 and has held it in 8 quarters since. The position peaked at $971K in Q2 2026. 88 funds tracked by Wall St. Rank hold MLYS as of Q3 2026.

  • Simplex Trading held 32,507 shares of Mineralys Therapeutics worth $817K as of Q3 2026.
  • Simplex Trading sold 3,472 Mineralys Therapeutics shares in Q3 2026, an estimated $94.5K.
  • Mineralys Therapeutics made up ﹤0.01% of Simplex Trading's portfolio in Q3 2026, its #2976 holding.
  • Simplex Trading first reported a position in Mineralys Therapeutics in Q3 2024 and has held it in 8 quarters since.
  • Simplex Trading's Mineralys Therapeutics position peaked at $971K in Q2 2026.
  • 88 funds tracked by Wall St. Rank held Mineralys Therapeutics as of Q3 2026.

Based on Simplex Trading's 13F filing for Q3 2026, filed 4 Nov 2026.